ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

January 25, 2013

ACS Reports Breast Cancer Incidence At All Time High

January 23, 1987

In Brief: President OK’s Mammography Standard Publication, CDC State Grants Increase

January 7, 1994

Komen Under Pressure: Charity Faces Money Woes, Attacks from Right

October 26, 2012

In Brief: DTP Combines Two Branches; Robert Cooper Names DCPC Board Chairman Weicker Receives MSK Award

June 28, 1985

Cooperative Groups Pursue Contracts With Insurers, NCI Warns of Competition

June 14, 1996